Clostridium difficile infection: An update on epidemiology, risk factors, and therapeutic options

Current Opinion in Gastroenterology

Volumn 28, Issue 1, 2012, Pages 1-9

  Lo Vecchio, Andrea ^a   Zacur, George M ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Clostridium difficile infection; Diarrhea

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID VACCINE; FIDAXOMICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; LFF 571; METRONIDAZOLE; MONOCLONAL ANTIBODY; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; FECES; HUMAN; INFECTION RISK; NONHUMAN; RECURRENT INFECTION; REVIEW; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INCIDENCE; INTESTINES; RISK FACTORS; UNITED STATES;

EID: 84857057604     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32834bc9a9     Document Type: Review

References (102)

1. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204.
2. Barbut F, Richard A, Hamadi K, et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000; 38:2386-2388. (Pubitemid 30414372)
3. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009; 58:403-410.
4. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431-455. Outstanding review and thorough guideline presentation for the diagnosis and management of CDI in adults based on a rigorous systematic review of the literature.
5. Cocanour CS. Best strategies in recurrent or persistent Clostridium difficile infection. Surg Infect (Larchmt) 2011; 12:1-5. Good review of current therapy recommendations for CDI and recurrent infections.
6. Pannerden CM, Verbon A, Kuipers EJ. Recurrent Clostridium difficile infection: what are the treatment options? Drugs 2011; 71:853-868. Thorough review of CDI with additional focus on recurrent infection algorithm, current therapy, and future potential treatments.
7. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549-557. (Pubitemid 41196754)
8. Bauer M, Notermans D, van Benthem B, et al. ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63-73. A survey involving 34 European countries conducted in 2008 demonstrating that the incidence of CDI varied across hospitals and countries. Discusses the different strains and their prevalence, as well as risk factors.
9. Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol 2011; 8:17-26. Good source of current information on epidemiology and evolving risk factors and at risk populations.
10. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97:1769-1775. (Pubitemid 34761404)
11. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-193. (Pubitemid 32108091)
12. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435-438. (Pubitemid 351263426)
13. Katchar K, Taylor CP, Tummala S, et al. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol 2007; 5:707-713. (Pubitemid 46830983)
14. Kelly CP, Kyne L. The host immune response to Clostridium difficile. J Med Microbiol 2011; 60:1070-1079. Excellent review of the most current literature pertaining to the immune system and the inflammatory response to CDI. Up-to-date information on active and passive immunity and their future role in CDI and recurrent infection.
15. Gilca R, Hubert B, Fortin E, et al. Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Quebec, Canada. Infect Control Hosp Epidemiol 2010; 31:939-947. An analysis and discussion of the epidemiology of CDI during epidemic and nonepidemic years in Montreal.
16. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142:624-631. (Pubitemid 47080440)
17. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006; 12:409-415.
18. Freeman J, Bauer MP, Baines SD, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010; 23:529-549. Excellent and comprehensive review of the evolving epidemiology of C. difficile infections including outbreaks, regional trends, and distribution of ribotypes.
19. Kutty PK, Woods CW, Sena AC, et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010; 16:197-204. A study that identifies patient risk factors and estimated incidence of CA-CD in North Carolina in 2005.
20. Centers for Disease Control and Prevention. Severe Clostridium difficile associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:1201-1205.
21. Centers for Disease Control and Prevention. Surveillance for community acquired Clostridium difficile infection: Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008; 57:340-343.
22. Lambert PJ, Dyck M, Thompson LH, Hammond GW. Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol 2009; 30:945-951.
23. Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis 2011; 24:370-376. Excellent review of current literature and presentation of epidemiology and guidelines for surveillance, prevention and control of CDI in healthcare facilities.
24. Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010; 10:395-404. Thorough update on CDI evolution and dissemination through a risk assessment framework. They discuss outbreak prevention.
25. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353:2442-2449. (Pubitemid 41770165)
26. Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42:758-764. (Pubitemid 43363928)
27. Miller M, Gravel D, Mulvey M, et al. Healthcare-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50:194-201.
28. Barbut F, Mastrantonio P, Delmee M, et al. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007; 13:1048-1057. (Pubitemid 47553515)
29. Akerlund T, Persson I, Unemo M, et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol 2008; 46:1530-1533. (Pubitemid 351563610)
30. Merrigan M, Venugopal A, Mallozzi M, et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010; 194:4904-4911. They compared hypervirulent and nonhypervirulent strains and studied their toxin production and sporulation.
31. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficileassociated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)- producing strains. J Med Microbiol 2005; 54:181-185. (Pubitemid 40868005)
32. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-2441. (Pubitemid 41770164)
33. Wilcox M. Clostridium difficile ribotyping network for England and Northern Ireland 2008/09 report. London: Health Protection Agency; 2009.
34. Hensgens MP, Goorhuis A, Notermans DW, et al. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro Surveill 2009; 14:pii19402.
35. Quesada-Gomez C, Rodriguez C, Gamboa-Coronado Mdel M, et al. Emergence of Clostridium difficile NAP1 in Latin America. J Clin Microbiol 2010; 48:669-670.
36. Riley TV, Thean S, Hool G, Golledge CL. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust 2009; 190:706-708.
37. Tae CH, Jung SA, Song HJ, et al. The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci 2009; 24:520-524.
38. Cheng VC, Yam WC, Chan JF, et al. Clostridium difficile ribotype 027 arrives in Hong Kong. Int J Antimicrob Agents 2009; 34:492-493.
39. Kato H, Ito Y, van den Berg RJ, et al. First isolation of Clostridium difficile 027 in Japan. Euro Surveill 2007; 12:E070111-E070113.
40. Hensgens MP, Goorhuis A, van Kinschot CM, et al. Clostridium difficile infection in an endemic setting in the Netherlands. Eur J Clin Microbiol Infect Dis 2011; 30:587-593. In this study, they look at risk factors for CDI in an endemic setting over 34 months in the Netherlands. This prospective case-control study found that risk factors for CDI in endemic settings differed from those in outbreak situations.
41. Limbago BM, Long CM, Thompson AD, et al. Clostridium difficile strains from community-associated infections. J Clin Microbiol 2009; 47:3004-3007.
42. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47:1162-1170.
43. Jhung MA, Thompson AD, Killgore GE, et al. Clostridium difficile in humans and food animals. Emerg Infect Dis 2008; 14:1039-1045. (Pubitemid 351920432)
44. Shakov R, Salazar RS, Kagunye SK, et al. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control 2011; 39:194-198.
45. Patriarchi F, Rolla M, Maccioni F, et al. Clostridium difficile-related pancolitis in lung-transplanted patients with cystic fibrosis. Clin Transplant 2011; 25:E46-51. The authors noticed that CF patients, despite their large use of antibiotic are usually at low risk of developing CDI; however, lung transplantation seems to be a risk factor for them. They describe three cases of severe CD colitis in patients with CF following lung transplantation.
46. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002; 23:653-659. (Pubitemid 35315987)
47. Bauer MP, van Dissel JT, Kuijper EJ. Clostridium difficile: controversies and approaches. Curr Opin Infect Dis 2009; 22:517-524.
48. Dubberke ER, Reske KA, Olsen MA, et al. Evaluation of Clostridium difficileassociated disease pressure as a risk factor for C. difficile-associated disease. Arch Intern Med 2007; 167:1092-1097. (Pubitemid 46835798)
49. McFarland LV. Update on the changing epidemiology of Clostridium difficileassociated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5:40-48.
50. Kim J, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium difficile-associated diarrhea. World J Gastroenterol 2010; 16:3573-3577.
51. Rupnik M, Songer JG. Clostridium difficile: its potential as a source of foodborne disease. Adv Food Nutr Res 2010; 60:53-66. Excellent discussion on the current state of C. difficile and the relationship to food products and contaminated meat. They address the potential for C. difficile to be a food-borne pathogen.
52. Zilberberg MD, Tillotson GS, McDonald LC. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010; 16:604-609. Thorough study that examined two large national databases. They calculated rates of CDI and increasing incidence in pediatric patients. The authors suggest that the increasing rates may be secondary to reporting bias for diarrheal illnesses.
53. Nylund CM, Goudie A, Garza JM, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011; 165:451-457. Excellent retrospective cohort study of CDI in hospitalized pediatric patients. They showed an increasing trend in cases between 1997 and 2006. In contrast to adults, there was no increasing trend in the severity of CDI in children.
54. Sandora TJ, Fung M, Flaherty K, et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011; 30:580-584. Case-control study on CDI in pediatrics. Risk factors discovered included solid organ transplant and gastrostomy or jejunostomy tube.
55. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15:1067-1079.
56. Shannon-Lowe J, Matherson NJ, Cooke FJ, et al. Prevention and medical management of Clostridium difficile infection. Br Med J 2010; 340:c1296. Excellent clinical review based on practical clinical question for the management of CDI.
57. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169-1172. (Pubitemid 16002615)
58. Bartlett JG. New drugs for Clostridium difficile infection. Clin Infect Dis 2006; 43:428-431. (Pubitemid 44157149)
59. Musher DM, Logan NL, Bressler AM, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double blind study. Clin Infect Dis 2009; 48:41-46.
60. Du Pont HL. The search for effective treatment of Clostridium difficile infection. N Engl J Med 2011; 364:473-475.
61. Nelson RL. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007:CD004610. doi: 10.1002/ 14651858.CD004610.pub3.
62. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008; 52:4163-4165.
63. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 48:4430-4434. (Pubitemid 39434908)
64. Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004; 48:2280-2282. (Pubitemid 38691631)
65. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008; 52:1391-1395. (Pubitemid 351522003)
66. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004; 48:4898-4902. (Pubitemid 39577704)
67. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51:2716-2719. (Pubitemid 47206204)
68. Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Exp Opin Pharmacother 2010; 11:1569-1578.
69. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-431. A large and well designed phase III study that compares fidaxomicin to vancomycin and demonstrates the noninferiority in term of CDI resolution and the superiority in reducing rate of recurrence.
70. Broekhuysen J, Stockis A, Lins RL, et al. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000; 38:387-394. (Pubitemid 30650157)
71. Dubreuil L, Houcke I, Mouton Y, Rossignol JF. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996; 40:2266-2270. (Pubitemid 26328028)
72. Musher DM, Logan N, Hamill RJ, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43:421-427. (Pubitemid 44157148)
73. Musher DM, Logan N, Mehendiratta V. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59:705-710. (Pubitemid 47073405)
74. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26: 17-25.
75. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44:846-848. (Pubitemid 46365312)
76. Garey KW, Jiang ZD, Bellard A, Du Pont H. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009; 43:91-92.
77. Lu CL, Liu CY, Liao CH, et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010; 35:311-312.
78. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48:1732-1735.
79. Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010; 38:755-758.
80. Russell G, Kaplan J, Ferraro MJ, et al. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010; 126:e239-e242. This is the first study of a child with an antibiotic and probiotic-resistant C. difficile infection, successfully treated with fecal bacteriotherapy.
81. Garborg K, Waagsbo B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhea. Scand J Infect Dis 2010; 42:857-861. This case series reports the largest population of patients in the past 30 years (40 adults with C. difficile-associated diarrhea) treated with donor fecal transplant.
82. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010; 44:562-566.
83. Rohlke F, Surawicz CM, Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010; 44:567-570.
84. Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011; 34:409-415. This is the most recent and updated review reporting on screening investigations, route of administration and effect of fecal transplant for C. difficile infection, irritable bowel syndrome and inflammatory bowel disease.
85. van Nood E, Speelman P, Kuijper EJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Eurosurveillance 2009; 34:1-6.
86. Buts JP. Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspective. Dig Dis Sci 2009; 54:18.
87. Kekkonen RA, Sysi-Aho M, Seppanen-Laakso T, et al. effect of probiotic Lactobacillus Rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol 2008; 14:3188-3194.
88. McFarland LV. Meta analysis of probiotics for prevention of antibiotic associated diarrhea and treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-822.
89. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-1017. (Pubitemid 32299362)
90. McFarland LV. Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections. Anaerobe 2009; 15:274-280.
91. Gao XV, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficileassociated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105:1636-1641. A recent randomized controlled trial showing the efficacy of a prophylaxis ith a blend containing different Lactobacillus strains in reducing the risk of antibioticassociated diarrhea and C. difficile diarrhea in hospitalized adults.
92. Pillai A, Nelson RL. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008:CD004611. doi: 10.1002/14651858.CD004611.pub2. (Pubitemid 351807675)
93. O'Donoghue C, Kyne L. Update on Clostridium difficile infection. Curr Opin Gastroenterol 2011; 27:38-47.
94. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe 2009; 15:281-284.
95. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011; 56:19-26. Excellent review and comparison of all literature in which IVIG was used. They found IVIG to be useful adjunctive treatment option in those who have failed initial therapies or in seriously ill patients in whom surgery is being considered.
96. Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med 2010; 5:e1-e9. Good observational study that reported IVIG was not beneficial in all patients.
97. Musgrave CR, Bookstaver PB, Sutton SS, Miller AD. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis 2011; 15:e438-e448. Comprehensive review of all therapies with a focus on newer and controversial treatments.
98. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362:197-205. Landmark study on the current and future use of monoclonal antibodies and their work.
99. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004; 22:848-856. (Pubitemid 38177385)
100. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005; 128:764-770. (Pubitemid 40585378)
101. Lee BY, Popovich MJ, Tian Y, et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010; 28:5245-5253. They developed an economic computer model that evaluated the cost-effectiveness of a CDI vaccine.
102. Gardiner DF, Rosenberg T, Zaharatos J, et al. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine 2009; 27:3598-3604.